Printer Friendly

MARK S. GERMAIN, MANAGING DIRECTOR OF D. BLECH & CO., RESIGNS FROM RIBI IMMUNOCHEM BOARD OF DIRECTORS

 HAMILTON, Mont., Jan. 15 /PRNewswire/ -- Ribi ImmunoChem Research Inc. (NASDAQ: RIBI) announced today that Mark S. Germain, managing director of D. Blech & Co. Inc., has resigned from Ribi's board of directors. The resignation of Germain, who was elected to the board in October 1991, reduces the number of directors to six.
 "We accept Mark's resignation with regret," said Robert E. Ivy, chief executive officer, president and chairman of Ribi ImmunoChem. "His legal and financial background was most appreciated during his tenure on our board. We realize, however, that his many commitments as managing director of D. Blech & Co. do not allow sufficient time for him to continue his service as a director of Ribi."
 Ribi ImmunoChem Research Inc., a biopharmaceutical company founded in 1981, is a leader in the development of immunostimulants for use in preventing and treating human and animal diseases.
 -0- 1/15/93
 /CONTACT: Jeffrey S. McDowell, corporate information manager, of Ribi ImmunoChem Research, 406-363-6214, ext. 153/
 (RIBI)


CO: Ribi ImmunoChem Research Inc. ST: Montana IN: MTC SU: PER

SW-JH -- SE006 -- 5518 01/15/93 16:30 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 15, 1993
Words:181
Previous Article:FREDA CORPORATION REPORTS GROSS REVENUES AND NET LOSS FOR THE FOURTH QUARTER AND NET LOSS FOR THE YEAR IN FISCAL 1992
Next Article:PRECISION CASTPARTS ANNOUNCES LAYOFFS
Topics:


Related Articles
ENHANCED SURVIVAL FOR MELANOMA PATIENTS ON RIBI THERAPY SUGGESTED BY NEW TEST FOR IMMUNOLOGICAL RESPONSE
RIBI IMMUNOCHEM'S RISING STOCK PRICE TRIGGERS S.R. ONE WARRANT EXERCISE
RIBI IMMUNOCHEM NAMES MEDICAL DIRECTOR, CREATES NEW PRODUCT DEVELOPMENT DIVISION
GYNEX PHARMACEUTICALS ANNOUNCES CHANGES IN BOARD OF DIRECTORS, CONTINUED OPERATIONAL ADVANCES
U.S PATENT ALLOWED COVERING USE OF MPL-C TO PREVENT, REDUCE ISCHEMIA-REPERFUSION INJURY
RIBI IMMUNOCHEM REPORTS 1994 FIRST QUARTER FINANCIAL RESULTS
RIBI IMMUNOCHEM NAMES VICE PRESIDENT-CORPORATE DEVELOPMENT
LXR BIOTECHNOLOGY INC. ANNOUNCES DR. EUGENE EIDENBERG ELECTED AS CHAIRMAN AT REGULAR OCTOBER BOARD MEETING
TEXAS BIOTECHNOLOGY APPOINTS NEW BOARD MEMBERS
RIBI IMMUNOCHEM ANNOUNCES STAFF APPOINTMENTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters